| Identification | Back Directory | [Name]
Cenicriviroc | [CAS]
497223-28-6 | [Synonyms]
TAK-652 Mesylate
TBR-652) mesylate
Cenicriviroc mesilate
CENICRIVIROC MESYLATE; TAK-652; TAK652; TAK 652; TBR-652; TBR 652; TBR652; CENICRIVIROC.
(5E)-8-[4-(2-Butoxyethoxy)phenyl]-1-isobutyl-N-(4-{(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
(S,E)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide methanesulfonate
(5E)-8-[4-(2-Butoxyethoxy)phenyl]-1-isobutyl-N-(4-{(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide methanesulfonate (1:1
1-Benzazocine-5-carboxamide,8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-,monomethanesulfonate | [Molecular Formula]
C41H52N4O4S.CH4O3S | [MDL Number]
MFCD28502077 | [MOL File]
497223-28-6.mol | [Molecular Weight]
793.05 |
| Chemical Properties | Back Directory | [Melting point ]
145.5-147.5 °C(Solv: 2-butanone (78-93-3)) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:100.0(Max Conc. mg/mL);126.1(Max Conc. mM) | [form ]
Solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Cenicriviroc Mesylate can be used as farnesoid X receptor (FXR) agonists. | [in vivo]
Cenicriviroc Mesylate (CVC) treatment leads to dose-related decrease in monocyte/macrophage recruitment, and achieving statistical significance at doses ≥20 mg/kg/day (p<0.05). Compare to the vehicle-control group, peritoneal lavage monocyte/macrophage counts are decreased by: 5.7%, 45.2%, 76.5% and 26.0% for Cenicriviroc Mesylate 5 twice daily (BID), Cenicriviroc Mesylate20 twice daily (BID), Cenicriviroc Mesylate100 BID, Cenicriviroc Mesylate 20 once-daily (QD), respectively. Exposure to Cenicriviroc Mesylate is dose-related and correlated with the decrease in monocyte/macrophage recruitment, with Cenicriviroc Mesylate appearing to be more effective when given BID versus QD, in line with the higher plasma concentrations achieved with BID dosing and the known short half-life in mice (~2 hours)[1]. | [IC 50]
CCR5: 0.29 nM (IC50); CCR2: 5.9 nM (IC50); R5 HIV-1: 0.024-0.08 nM (IC50, in PBMCs); R5 HIV-2: 0.03-0.98 nM (IC50, in PBMCs) |
|
|